Curodont global rollout backed by apollo
Apollo minority investment to accelerate vVARDIS’s global rollout of Curodont Introduction / background ZUG, Switzerland — vVARDIS, the privately held Swiss medical‑technology company behind the peptide‑based Curodont technology for non‑invasive treatment of early carious lesions, has announced a strategic minority investment by funds managed by Apollo, a global alternative asset manager. The company reported that […]
